• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Agios Touts Encouraging Action From Sickle Cell Disease Study With Mitapivat

cafead

Administrator
Staff member
  • cafead   Jun 26, 2023 at 09:12: PM
via Agios Pharmaceuticals Inc (NASDAQ: AGIO) announced that the Phase 2 portion of the global Phase 2/3 RISE UP study of mitapivat in sickle cell disease met its primary endpoint of hemoglobin response.

article source
 

<